Search

Search Constraints

You searched for: Author/Creator Gimsing, Peter

Search Results

2. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Issue 6 (June 2020)

3. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Issue 6 (June 2020)

4. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case‐matched study. Issue 4 (5th February 2014)

5. Causes of early death in multiple myeloma patients treated with high‐dose therapy followed by autologous stem cell transplantation: A study based on the nationwide Danish Multiple Myeloma Registry. Issue 10 (17th August 2017)

6. Causes of early death in multiple myeloma patients who are ineligible for high‐dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database. Issue 4 (2nd February 2015)

9. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner. Issue 2 (30th December 2017)

10. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. Issue 1 (2nd January 2019)